Eli Lilly 2006 Annual Report Download - page 9

Download and view the complete annual report

Please find page 9 of the 2006 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 116

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116

PORTFOLIO AND PIPELINE
7
1987 Humatrope® for growth failure caused by pediatric growth hormone defi ciency
for replacement therapy for adult growth hormone defi ciency (1995)
for short stature caused by Turner syndrome (1997)
for idiopathic short stature (2003)
1983 Humulin® for type 1 and type 2 diabetes
New Drug Application Submitted For Review to the U.S. Food and Drug Administration
Arxxant™ (ruboxistaurin) for diabetic retinopathy
Select Drug Candidates in Late-Stage Investigation
Prasugrel for acute coronary syndromes
(codeveloping with Daiichi Sankyo Company, Ltd.)
Inhaled insulin for type 1 and type 2 diabetes
(codeveloping with Alkermes, Inc.)
Arzoxifene for prevention and treatment of osteoporosis and for reducing the risk of breast
cancer, all in postmenopausal women
Enzastaurin for non-Hodgkin’s lymphoma (phase III); for metastatic breast cancer, colorectal
cancer, non-small-cell lung cancer, and ovarian cancer (phase II)
Olanzapine pamoate for intramuscular delivery for schizophrenia
Select Drug Candidates in Mid-Stage Investigation
Pruvanserin for insomnia
(5-HT2A antagonist)
PPAR alpha agonist for reducing the progression of atherosclerosis
(LY518674)
Survivin ASO for solid tumors
A-beta lowering for Alzheimer’s disease
(Gamma secretase inhibitor)
A-beta antibody for Alzheimer’s disease
ASAP for solid tumors
mGluR3 antagonist for migraine
NERI IV for depression (phase II); for ADHD (phase I)
mGlu2/3 prodrug for schizophrenia
IL-1 beta antibody for rheumatoid arthritis
Gemcitabine prodrug for solid tumors
GLP-1 analog for type 2 diabetes
Glucokinase activator for type 2 diabetes (recently in-licensed from OSI Pharmaceuticals, Inc.)
Information is current as of January 18, 2007. The search for new drugs is risky and uncertain, and there are no guarantees. Remaining scientifi c and
regulatory hurdles may cause pipeline compounds to be delayed or even to fail to reach the market.